NCT07158411View on ClinicalTrials.gov

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Healthy Participants
Interventions
DRUG

Vimseltinib

Administered orally

DRUG

Metformin

Administered orally

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY